Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245 is registered in ClinicalTrials.gov with OSE Immunotherapeutics as lead sponsor.

NCT NCT06472245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06472245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor
Lead sponsor
OSE Immunotherapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
December 3, 2024
Completion date
December 15, 2028
Enrollment
363 (estimated)
Sites
207

Conditions

As the registry lists them; a condition with its own page is linked.

patients with non-small cell lung cancer